or buy back some stock... this would not only keep the shorts guessing but also signal management's confidence in the firm going forward.
The way i see ACR at the moment is a fully funded biotech option - IF (and thats a big IF) they can actually come up with another application / product from their pipeline, the upside could be large (noting that historically ACR has struggled to commercialise much outside of Axiron).
If they can't commercialise anything new, the downside is also limited - as based on the Axiron cashflows alone this thing is worth at least $1 per share (not counting any further milestones and limited international expansion).
Lets see what that new CEO can do in the new product space...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 460415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 10005 | 2 |
View Market Depth
| Last trade - 08.28am 24/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable